| 摘要 |
[Problems] To provide a marker as a guideline which serves as a measure for the treatment of breast cancer. [Means for solving] A kit and/or a method for the diagnosis of breast cancer, which includes an anti-LAT1 monoclonal antibody. Among intraductal breast neoplastic lesions, duct carcinoma in situ, which is malignant, undergoes the expression of LAT1 at a significantly high level compared to intraductal breast papilloma, which is benign. Therefore, an anti-LAT1 monoclonal antibody is useful for the discrimination between the two lesions. Further, LAT1 is expressed at a high level in most of triple negative infiltrating carcinomas which are negative for all of ER, PgR, and HER2 that are conventional molecular targeting markers for breast cancer and for which there is no proper molecular-targeted therapy method. Therefore, LAT1 can be used as a novel molecular targeting marker for breast cancer. To diagnosis the LAT1 by the present immunohistological method, and the development of a molecular-targeted therapy method targeting the LAT1 are effective. |
